Taysha Gene Therapies (NASDAQ:TSHA) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.
This table compares Taysha Gene Therapies and Cardiff Oncology’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Taysha Gene Therapies||N/A||-45.81%||-41.58%|
This table compares Taysha Gene Therapies and Cardiff Oncology’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Taysha Gene Therapies||N/A||N/A||-$60.01 million||($3.40)||-5.53|
|Cardiff Oncology||$370,000.00||729.04||-$19.31 million||($1.08)||-6.31|
Cardiff Oncology has higher revenue and earnings than Taysha Gene Therapies. Cardiff Oncology is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
46.1% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 67.1% of Cardiff Oncology shares are owned by institutional investors. 41.8% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 4.6% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of current recommendations for Taysha Gene Therapies and Cardiff Oncology, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Taysha Gene Therapies||0||0||13||0||3.00|
Taysha Gene Therapies currently has a consensus target price of $44.31, indicating a potential upside of 135.68%. Cardiff Oncology has a consensus target price of $25.33, indicating a potential upside of 271.46%. Given Cardiff Oncology’s higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than Taysha Gene Therapies.
Cardiff Oncology beats Taysha Gene Therapies on 7 of the 11 factors compared between the two stocks.
Taysha Gene Therapies Company Profile
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.
Cardiff Oncology Company Profile
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm’s clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.